文献速递炎症性肠病肝病

维得利珠单抗对原发性硬化性胆管炎合并炎症性肠病患者的影响

Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-05-14

研究收集国际PSC研究组中102例接受至少3剂维得利珠单抗的PSC合并IBD患者数据,中位治疗412天。整个队列中位ALP从基线1.54倍正常上限升至末次随访1.64倍正常上限(P= .018),21例(20.6%)ALP下降≥20%;肝硬化是ALP下降≥20%的独立相关因素(OR 4.48,P= .019)。作者结论为未发现维得利珠单抗的生化应答证据,但部分患者ALP下降≥20%,药物似乎耐受良好,IBD总体应答与无PSC患者相同。

要点

  • 整个队列中位ALP从基线1.54倍正常上限升至末次随访1.64倍正常上限(P= .018)。
  • 21例(20.6%)患者ALP下降≥20%,肝硬化是独立相关因素(OR 4.48,P= .019)。
  • 有内镜资料的患者中56.8% IBD治疗有应答;21例(20.6%)发生肝脏相关事件。

核心结论

  • 在PSC合并IBD的国际研究组患者中,未发现维得利珠单抗的生化应答证据,但部分患者ALP下降≥20%;维得利珠单抗似乎耐受良好,IBD总体应答与无PSC患者相同。

研究设计与样本

  • 国际多中心队列研究,收集欧洲和北美参与国际PSC研究组的PSC合并IBD患者,接受至少3剂维得利珠单抗(n=102),中位治疗412天。

主要发现

  • 整个队列中位ALP从基线1.54倍正常上限升至末次随访1.64倍正常上限(P= .018),转氨酶和胆红素也有小幅升高。
  • 21例(20.6%)患者ALP下降≥20%;仅肝硬化与ALP下降≥20%独立相关(OR 4.48,P= .019)。
  • 有内镜资料的患者中56.8% IBD治疗有应答;21例(20.6%)发生肝脏相关事件,包括细菌性胆管炎、肝硬化失代偿或移植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel diseases (IBD), but there are few data on its efficacy in patients with PSC. We investigated the effects of vedolizumab in a large international cohort of patients with PSC and IBD. METHODS: We collected data from European and North American centers participating in the International PSC Study Group from patients with PSC and IBD who received at least 3 doses of vedolizumab (n = 102; median vedolizumab treatment duration, 412 days). Demographic and clinical data were collected from baseline and during the follow-up period (until liver transplantation, death, or 56 days after the final vedolizumab infusion). We analyzed overall changes in biochemical features of liver and proportions of patients with reductions in serum levels of alkaline phosphatase (ALP) of 20% or more, from baseline through last follow-up evaluation. Other endpoints included response of IBD to treatment (improved, unchanged, or worsened, judged by the treating clinician, as well as endoscopic score) and liver-related outcomes. RESULTS: In the entire cohort, the median serum level of ALP increased from 1.54-fold the upper limit of normal at baseline to 1.64-fold the upper limit of normal at the last follow-up examination (P = .018); serum levels of transaminases and bilirubin also increased by a small amount between baseline and the last follow-up examination. Serum levels of ALP decreased by 20% or more in 21 patients (20.6%); only the presence of cirrhosis (odds ratio, 4.48; P = .019) was independently associated with this outcome. Of patients with available endoscopic data, 56.8% had a response of IBD to treatment. Liver-related events occurred in 21 patients (20.6%), including bacterial cholangitis, cirrhosis decompensation, or transplantation. CONCLUSIONS: In an analysis of patients with PSC and IBD in an international study group, we found no evidence for a biochemical response to vedolizumab, although serum level of ALP decreased by 20% or more in a subset of patients. Vedolizumab appears to be well tolerated and the overall response of IBD was the same as expected for patients without PSC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lynch KD, Chapman RW, Keshav S, et al. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019. PMID: 31100458. doi:10.1016/j.cgh.2019.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。